Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Short Interest Up ∞ in May

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) saw a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 758,697 shares, a growth of ∞ from the April 30th total of 0 shares. Based on an average trading volume of 622,622 shares, the days-to-cover ratio is currently 1.2 days. Approximately 1.7% of the shares of the company are short sold.

Wall Street Analyst Weigh In

A number of brokerages have issued reports on COAG. The Goldman Sachs Group began coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued a “buy” rating and a $36.00 price target for the company. Evercore initiated coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price target for the company. Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Wedbush initiated coverage on Hemab Therapeutics in a research note on Tuesday, May 26th. They set an “outperform” rating and a $42.00 target price for the company. Finally, Zacks Research raised Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, Hemab Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $41.75.

Hemab Therapeutics Trading Up 1.3%

Shares of COAG stock opened at $27.47 on Wednesday. Hemab Therapeutics has a 1-year low of $23.00 and a 1-year high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last announced its earnings results on Thursday, May 21st. The company reported ($23.98) earnings per share for the quarter.

Insider Transactions at Hemab Therapeutics

In related news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the firm’s stock in a transaction on Monday, May 4th. The stock was bought at an average cost of $18.00 per share, with a total value of $48,150,000.00. Following the completion of the acquisition, the director owned 6,149,096 shares of the company’s stock, valued at $110,683,728. The trade was a 77.00% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders purchased 2,902,872 shares of company stock valued at $53,769,784 over the last three months.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.